AUA2026: Focus on: Metastatic Urothelial Carcinoma

CME Available: https://cme.auanet.org/URL/FOCUS264ONL

LEARNING OBJECTIVES:

After participating in this CME activity, participants will be able to:

1. Select appropriate first-line therapies for patients with locally advanced or metastatic urothelial carcinoma during initial treatment planning, in accordance with updated NCCN guidelines.

2. Evaluate holistic management approaches, including treatment sequencing, therapy transitions, and long-term follow-up for patients with locally advanced or metastatic urothelial carcinoma throughout the course of disease.

3. Implement strategies to recognize, monitor, and mitigate treatment-related adverse events in patients receiving systemic therapy for locally advanced or metastatic urothelial carcinoma.

4. Integrate shared decision-making tools and communication strategies into clinical practice to ensure alignment of treatment choices with patient values and caregiver input.

5. Distinguish between treatment pathways for different stages of advanced bladder cancer, including variant histologies to ensure accurate staging and appropriate therapy selection based on the latest NCCN guidelines.

ACKNOWLEDGEMENTS

Support provided by independent educational grants from:

Merck & Co., Inc.

Pfizer, Inc.

AUA Guidelines: Clinically Localized Prostate Cancer

Host: Mark L. Gonzalgo, MD, PhD, MBA

Guest: James Eastham, MD, FACS

To access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/clinically-localized-prostate-cancer

Update Series (2026): Kidney Stones and the Infected Patient

Host: Mark L. Gonzalgo, MD, PhD, MBA

Guest: Mantu Gupta, MD

Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.

For more information or to subscribe to the AUA Update Series, please visit CME.auanet.org

AUA2026: Focus on: Biomarkers, MRI and PSMA PET Imaging in Prostate Cancer Webcast

CME Available: https://cme.auanet.org/URL/FOCUS262ONL

LEARNING OBJECTIVES:

After participating in this CME activity, participants will be able to:

1. Critically appraise recent developments in imaging biomarkers and molecular diagnostics (e.g., genomic risk scores, liquid biopsy) and discuss how they complement MRI and PSMA PET in prostate cancer care.

2. Determine the optimal clinical scenarios (diagnostic, staging, recurrence, surveillance) in which PSMA PET/CT or PET/MRI adds value beyond conventional imaging.

3. Recognize potential pitfalls in PSMA PET interpretation — including false positives, false negatives, non–PSMA-expressing disease, and technical artifacts — and implement strategies to mitigate them.

4. Synthesize biomarker, MRI, and PSMA PET findings into a personalized management plan, including guiding biopsy, focal therapy, salvage therapy, or systemic treatments.

5. Select appropriate patients with radiorecurrent or organ-confined prostate cancer for advanced imaging and guide re-treatment decisions (e.g., salvage therapy, targeted radiotherapy).

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from:

Blue Earth Diagnostics, Inc.

Lantheus Medical Imaging

AUA2026 Spotlight: PARP-Inhibitor Combination Treatments for the Urologic Care Team

CME Available: https://cme.auanet.org/URL/PARP26ONL

LEARNING OBJECTIVES:

At the conclusion of this CME activity, participants will be able to:

1. Integrate biomarker and genetic testing principles into clinical workflows for patients with metastatic prostate cancer, including when to order testing, how to interpret HRR mutation results (inclusive of BRCA and non-BRCA), and how to address barriers to testing through multidisciplinary coordination.

2. Explain the mechanism of action of PARP inhibitors and the biological and clinical rationale for their use—both as monotherapy and in combination approaches—in the treatment of mPC.

3. Evaluate emerging efficacy and safety data on PARPi combinations, including patient subgroup analyses, sequencing strategies, and the role of combination therapy in different stages of mPC.

4. Apply best practices for side effect monitoring and mitigation in patients receiving PARP inhibitors alone or in combination, leveraging the multidisciplinary team for optimal therapy management and patient quality of life.

5. Implement guideline-concordant care strategies in practice, including genetic testing workflow implementation, coordination among care team members, and patient engagement in shared decision-making and clinical trial enrollment.

5. Utilize current evidence-based guidelines to select and sequence PARP inhibitor therapy for patients with mPC, optimizing oncologic outcomes while individualizing care based on molecular profile and patient-specific factors.

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from:

Astrazeneca

Merck & Co., Inc

Pfizer, Inc.

Update Series (2026) Lesson 15: Case-Based Testicular Cancer Clinical Practice Guidelines

Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.

For more information or to subscribe to the AUA Update Series, please visit cme.auanet.org/URL/US2026

AUA Guidelines: Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia

Host: Mark L. Gonzalgo, MD, PhD, MBA

Guest: Jaspreet S. Sandhu, MD

To access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/bph-guideline.

Please note that access to the full guideline requires user login. If you do not already have an account, you can create a free login.

AUA2026: Society of Women in Urology Meeting

Host: Mark L. Gonzalgo, MD, PhD, MBA

Guest: Amy N. Luckenbaugh, MD, FACS

To register for AUA2026, please visit auanet.org/AUA2026/register!

AUA2026: Society of Urologic Oncology Meeting

Host: Mark L. Gonzalgo, MD, PhD, MBA

Guest: Dr. Kelvin A. Moses, MD, PhD & Dr. Mark A. Preston, MD, MPH

To register for AUA2026, please visit auanet.org/AUA2026/register!

AUA2026: Society of Benign Prostate Disease Meeting

Host: Mark L. Gonzalgo, MD, PhD, MBA

Guest: Kevin Thomas McVary, MD, FACS

To register for AUA2026, please visit auanet.org/AUA2026/register!